Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

112
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

97
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
97
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

117
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
117
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Human Genetics01:28

Human Genetics

1.9K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.9K
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

171
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
171

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antipsychotic action and symptom specificity - down the bioinformatic rabbit hole.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Multiple Sclerosis in Charcot-Marie-Tooth Disease Type 1A - A Case Report and Literature Review.

Journal of central nervous system disease·2026
Same author

Developing a Polygenic Risk Score for Weight Gain in People Treated for Psychosis-Application in a Real-World Setting.

Human psychopharmacology·2026
Same author

Extracts of Black Glutinous Rice Influenced Memory Impairment and Anxiety-Like Behavior associated with Kidney Stones in Rats.

Preventive nutrition and food science·2026
Same author

Differential protein expression profiles in human sperm from teratozoospermic and normozoospermic men identify LTBP1 and TGF-βR1 as potential biomarkers within the TGF-β signalling pathway.

PloS one·2026
Same author

Fecal Metabolomic Insights into Memory-Associated Pathways Modulated by <i>Bacopa monnieri</i>, Mixed Thai Berry, and Combined Extracts in Rats Under Chronic Unpredictable Mild Stress.

Antioxidants (Basel, Switzerland)·2026

Related Experiment Video

Updated: Apr 3, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

16.0K

BDNF (Val66Met) genetic polymorphism is associated with vulnerability for methamphetamine dependence.

Sri-Arun Iamjan1,2, Samur Thanoi1,2, Paritat Watiktinkorn3

  • 1Department of Anatomy, Faculty of Medical Science, Naresuan University, Phitsanulok 65000, Thailand.

Pharmacogenomics
|September 25, 2015
PubMed
Summary

The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism (rs6265) is linked to methamphetamine dependence in Thais. The GG genotype is more common in dependent individuals but may protect against psychosis.

Keywords:
BDNFmethamphetamine dependencepolymorphismpsychosisrs6265

More Related Videos

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.5K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.7K

Related Experiment Videos

Last Updated: Apr 3, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

16.0K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.5K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.7K

Area of Science:

  • Neuroscience
  • Genetics
  • Psychiatry

Background:

  • Methamphetamine (METH) dependence is a significant public health issue.
  • Genetic factors, including brain-derived neurotrophic factor (BDNF) polymorphisms, may influence susceptibility to METH dependence and psychosis.
  • The BDNF Val66Met (rs6265) polymorphism is a candidate gene for METH-related disorders.

Purpose of the Study:

  • To investigate the association of the BDNF rs6265 (Val66Met) polymorphism with METH dependence.
  • To examine the relationship between rs6265 genotype and METH-induced psychosis in the Thai population.

Main Methods:

  • Genotyping of the BDNF rs6265 polymorphism was performed using a real-time PCR high-resolution melt (RT-PCR-HRM) assay.
  • A case-control study design was employed, including 100 male METH-dependent subjects and 102 healthy controls.

Main Results:

  • Significant differences in rs6265 genotype distribution were observed between METH-dependent subjects and controls.
  • The GG genotype was more frequent in METH-dependent individuals compared to A-allele carriers.
  • A lower frequency of the GG genotype was associated with METH-induced psychosis, suggesting a protective effect.

Conclusions:

  • The BDNF rs6265 polymorphism is associated with METH dependence in the Thai population.
  • The GG genotype appears to increase the risk of METH dependence while potentially reducing the likelihood of developing METH-induced psychosis.